REVIEW

Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible? [version 1; peer review: 2 approved]

Anthony D. Harries ^{1,2}, Amitabh B. Suthar³, Kudakwashe C. Takarinda ^{1,4}, Hannock Tweya^{1,5}, Nang Thu Thu Kyaw^{1,6}, Katie Tayler-Smith ⁷, Rony Zachariah⁷

¹International Union against Tuberculosis and Lung Disease, Paris, France

²Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK

³South African Centre for Epidemiological Modelling and Analysis (SACEMA), University of Stellenbosch, Stellenbosch, South Africa

⁴AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe

⁵The Lighthouse Trust, Kamuzu Central Hospital, Lilongwe, Malawi

⁶International Union Against Tuberculosis and Lung Disease, Myanmar Country Office, Mandalay, Myanmar

⁷Médecins sans Frontières, Operational Research Unit (LuxOR), Operational Centre Brussels, Luxembourg, Luxembourg

V1 First published: 15 Sep 2016, 5(F1000 Faculty Rev):2328
<https://doi.org/10.12688/f1000research.9247.1>

Latest published: 15 Sep 2016, 5(F1000 Faculty Rev):2328
<https://doi.org/10.12688/f1000research.9247.1>

Abstract

The international community has committed to ending the epidemics of HIV/AIDS, tuberculosis, malaria, and neglected tropical infections by 2030, and this bold stance deserves universal support. In this paper, we discuss whether this ambitious goal is achievable for HIV/AIDS and what is needed to further accelerate progress. The joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 targets and the related strategy are built upon currently available health technologies that can diagnose HIV infection and suppress viral replication in all people with HIV. Nonetheless, there is much work to be done in ensuring equitable access to these HIV services for key populations and those who remain outside the rims of the traditional health services. Identifying a cure and a preventive vaccine would further help accelerate progress in ending the epidemic. Other disease control programmes could learn from the response to the HIV/AIDS epidemic.

Keywords

HIV , AIDS , UNAIDS , antiretroviral therapy

Open Peer Review

Approval Status

	1	2
version 1 15 Sep 2016		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Ali Zumla**, University College London, London, UK

2. **Fabio Mesquita**, University of Sao Paulo, Sao Paulo, Brazil

Any comments on the article can be found at the end of the article.

Corresponding author: Anthony D. Harries (adharries@theunion.org)

Competing interests: The authors declare that they have no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2016 Harries AD *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Harries AD, Suthar AB, Takarinda KC *et al.* **Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible? [version 1; peer review: 2 approved]** F1000Research 2016, 5(F1000 Faculty Rev):2328 <https://doi.org/10.12688/f1000research.9247.1>

First published: 15 Sep 2016, 5(F1000 Faculty Rev):2328 <https://doi.org/10.12688/f1000research.9247.1>

Introduction

On 1 January 2016, we entered the new era of the Sustainable Development Goals (SDGs) that will guide the development agenda of the international community for the next 15 years up to 2030. Within these goals, the international community has committed to a bold agenda (SDG.3.4) of ending the epidemics of HIV/AIDS, tuberculosis, malaria, and neglected tropical infections by 2030¹. This vision deserves widespread support. In this paper, we discuss whether this ambitious goal is achievable for HIV/AIDS by 2030 and what is further needed to accelerate progress towards ending the epidemic.

Achievements and challenges in HIV/AIDS up to 2015

The Millennium Development Goals (MDGs) were conceived in 2000 with MDG 6 aiming to halt and reverse the spread of HIV/AIDS by 2015 (similar targets were set for tuberculosis and malaria). For HIV/AIDS, this goal was achieved. From 2001 to 2013, the annual incidence of HIV infections decreased by 38%, from 3.4 million in 2001 to 2.1 million in 2013². From 2002 to 2013, the annual incidence of HIV infections in children decreased by 58%, with 240,000 new infections in 2013 compared with 580,000 in 2002². In some regions of the world, mother-to-child transmission of HIV has been virtually eliminated². AIDS-related deaths also decreased by 35% between 2005 (when the highest number of deaths was recorded) and 2013³.

Despite this laudable progress, HIV/AIDS remains a major public health threat. In 2015, at the end of the MDG era, there were still an estimated 2.1 million new HIV infections worldwide, adding up to a total of 36.7 million people living with HIV/AIDS, and there were 1.1 million deaths³. Enormous challenges continue. Although knowledge of HIV status amongst people living with HIV is higher than before, more than half do not know they are infected with HIV⁴. In many countries, there are key populations in whom HIV incidence and AIDS-related mortality are much higher than in the general population: adolescent girls, sex workers, men who have sex with men (MSM), transgender people, people who inject drugs, prisoners, and migrants⁴. Structural and legal barriers impede technical progress. For example, same-sex sexual acts are criminalised in 78 countries and are punishable by death in seven⁴. Sex work is illegal and criminalised in 116 countries and, almost everywhere, illegality and criminalisation envelope persons who inject drugs⁴. These barriers make it difficult for some of the key populations to access HIV services. Indeed, in some countries in Central Asia, Eastern Europe, the Middle East, and North, West, and Central Africa with limited access to services for key populations, the number of new HIV infections is rising⁴. In addition, reaching populations affected by conflict and humanitarian crises and migrants (internal and cross-border) is a challenge now and will be in the years to come.

The scale up of antiretroviral therapy (ART) has been one of the major public health success stories of our time, with 17 million people accessing ART by the end of 2015 – 2 million more than the 15 million target set by the United Nations General Assembly in 2011³. Global coverage of ART reached 46% at the end of 2015, with the greatest gains made in the world's worst-affected regions of East and Southern Africa. South Africa alone had nearly

3.4 million people on treatment. However, coverage globally is not uniform. Eastern Europe and Central Asia, for example, have seen little expansion in ART scale up in the last few years. Treatment coverage is also often worse among men compared with women, with men frequently initiating treatment late and adhering poorly to medication³.

Finally, for HIV/AIDS, there has been a significant funding gap relative to the resources needed to fully address the epidemic, and the gap is growing. This problem is acute in some low- and middle-income countries where external financing is reducing and domestic resources do not match needs^{2,4}.

The response to HIV/AIDS and ending the epidemic

Given the size of the problem and on-going challenges with HIV/AIDS, what makes us think that the goal of ending the AIDS epidemic can be achieved? First, there is compelling evidence that certain biomedical interventions can significantly reduce new HIV infections and AIDS-related mortality. The key measures are the diagnosis of HIV infection and the sustained provision of ART to all those diagnosed with HIV. Treatment for HIV, especially when given immediately after diagnosis irrespective of CD4 count or World Health Organization (WHO) clinical stage, substantially reduces the risk of illness and death in the individual, and this has been shown conclusively in randomised controlled trials^{5,6}. The benefits of immediate ART also go beyond those for individual patients. Immediate ART reduces the risk of sexual transmission of HIV, this benefit having been demonstrated not only in clinical trials but also in the real world setting^{7,8}. Immediate ART reduces the risk of acquiring herpes simplex virus type-2 infection⁹, decreases the risk of tuberculosis¹⁰, provides concurrent treatment for hepatitis B infection, and obviates the current problem of poor retention in pre-ART care¹¹. Option B+, the current recommended strategy for preventing mother-to-child transmission, has immediate ART at its core and, by offering lifelong treatment to HIV-infected pregnant and breastfeeding mothers regardless of CD4 cell count or WHO clinical stage, has significant benefits for HIV transmission prevention and maternal health¹².

This body of knowledge prompted the joint United Nations Program on HIV/AIDS (UNAIDS) to release new 90-90-90 treatment targets for HIV¹³. These targets specify that by 2020, 90% of individuals living with HIV will know their HIV status, 90% of people with diagnosed HIV infection will receive sustained ART, and 90% of those on ART will be virally suppressed. If this three-part strategy is achieved, nearly three-quarters of all people living with HIV will be on treatment and virally suppressed by 2020. Modelling studies suggest that this outcome will enable the world to end the AIDS epidemic by 2030, defined as a 90% reduction in both incidence of HIV and AIDS-related mortality¹³.

Knowledge of HIV status

The first key measure is knowledge of HIV status. The development of inexpensive, sensitive, specific, rapid, and simple-to-use diagnostic tests has allowed HIV testing to be scaled up, decentralised, and undertaken when necessary by non-laboratory-based personnel. Currently available third-generation rapid tests are able to detect HIV antibodies approximately 21 days after exposure; research

is also on-going to reduce false negative tests during this three-week window period¹⁴. While the greatest diagnostic yields come from provider-initiated testing and counselling at health facilities, the need to increase case detection at the population level and to diagnose HIV earlier in the course of infection has led to a broad array of community-based approaches targeting asymptomatic people outside of health facilities, including home-based, mobile, workplace, school, self, and campaign-oriented testing^{2,15}. Self-testing is emerging as a useful and potentially supplementary way to increase the proportion of people who know their HIV status¹⁶. Point-of-care HIV testing, using oral fluid rapid tests and carried out by peers, has also been successfully introduced at social venues in Brazil for key hard-to-reach populations such as transgender people, MSM, and commercial sex workers, and this has resulted in improved access to HIV testing¹⁷. With all of these methods, though, it is crucial that there is good linkage to ART, and innovative approaches (such as additionally offering home initiation of treatment) need to be pilot tested and scaled up¹⁶.

Safe and effective ART with the response closely monitored

The second key measure is provision of safe and effective ART. Treatment has come a long way since combination therapy was first shown to be effective in reducing morbidity and mortality in patients with advanced HIV infection in developed countries in the mid-1990s¹⁸. Costs have plummeted and the current WHO-recommended first-line regimen of tenofovir-lamivudine (emtricitabine)-efavirenz is effective, safe, and non-toxic and is taken as a single pill once a day¹⁹. Further work being done on a lowered dose of efavirenz and improved safety of a novel tenofovir prodrug holds promise that this single-dose, one-pill-a-day regimen will become largely devoid of side effects and will require little or no laboratory monitoring in the future^{20,21}. The development of safe, effective, and non-toxic medication paved the way for the WHO to recommend that ART should be offered to all persons living with HIV regardless of clinical stage or CD4 cell count^{22,23}. Monthly or less frequent dosing by using long-acting injectable therapeutics (“depo-drugs”) could further improve adherence and treatment outcomes in the future²⁴.

Monitoring the response to ART is crucial. Some countries with limited resources, such as Malawi, have managed through a public health approach to monitor the numbers of people living with HIV who initiate ART and, of those, the numbers who are alive and retained in care, are dead, are lost to follow-up, have discontinued therapy, or have transferred from one ART clinic to another²⁵. While programmatic treatment outcomes are important for assessing effectiveness and for planning the resources needed on the ground, the measurement of viral load is key for assessing whether ART is effective and whether HIV disease is progressing or drug resistance is developing². Current viral load technologies are laboratory based and costly, so there is an urgent need to invest in, develop, and roll out low-cost, point-of-care viral load tests that can be used to monitor ART at all levels of the health system to determine whether drug adherence is poor (and therefore correctable) or whether a switch in treatment regimen is needed. At the Durban XXI International AIDS Conference in July 2016, it was clear that several new

point-of-care viral load tests have already been assessed and should be ready soon to be deployed in the field – this is where investments need to be made with viral load testing replacing CD4 cell count technology.

Other HIV prevention measures

While scale up and implementation of HIV testing and ART initiation for those HIV infected in different epidemic settings are essential to the global strategy, it is well recognised that a combination response with other well-proven interventions (pre-exposure prophylaxis [PrEP] with antiretroviral drugs, voluntary medical male circumcision, condom promotion, behaviour change programmes, opioid drug substitution, needle and syringe exchange programmes, and outreach programmes for MSM and sex workers) that depend on country and context will be needed to achieve maximum benefit^{2,26}.

For PrEP, the science is now clear that a co-formulation of oral tenofovir and emtricitabine significantly reduces the risk of HIV infection among non-HIV-infected persons at high risk of acquiring infection²⁷. Randomised controlled trials and open-label extension studies have shown the efficacy of this approach in MSM^{28,29}, heterosexual men and women in HIV-discordant relationships^{30,31}, and people who inject drugs³². The studies that have shown no benefit of PrEP have identified poor adherence to medication as the main culprit³³. Expanding access to PrEP is therefore not only sound public health policy but also a human rights imperative, and this strong addition to the HIV prevention arsenal has been recognised in the recent WHO Consolidated Guidance on treating and preventing HIV^{22,23}.

Voluntary male medical circumcision is another proven HIV prevention strategy that was tested in three randomised trials between 2005 and 2007 in South Africa, Kenya, and Uganda^{34–36}. The results showed that male medical circumcision reduced HIV acquisition in men by about 60%. Other benefits of this surgical approach to HIV prevention include a decrease in incidence of herpes simplex virus type-2 and human papillomavirus infection³⁷. Since 2008, the uptake of voluntary medical male circumcision has increased rapidly, with more than 10 million procedures performed by September 2015²⁶.

The contribution of different interventions will vary depending on the epidemic setting². For example, in generalised epidemics, the scale up of ART, especially immediate start of treatment, could contribute the most to a reduction in new infections, followed by condoms, PrEP, voluntary male medical circumcision, outreach to sex workers, and behaviour change communications. In epidemics driven by injecting drug use, the major contributors to a reduction in new infections could come from opioid drug substitution, needle and syringe exchange programmes, and the strategic use of ART. As countries move towards epidemic control targets, innovative and more efficient service delivery models that include improved diagnostic tools and longer-acting antiretroviral drugs will likely further accelerate progress towards ending the epidemic.

Addressing structural, legal, and social barriers

Several structural factors are recognised as being key to the HIV/AIDS response, and these need to be addressed to maximise the chances of achieving the target goal by 2030². For example, the completion of secondary education reduces vulnerability to HIV infection, with the effects particularly seen in girls³⁸. Violence prevention and HIV programming can have potential benefits, especially when integrated into community empowerment schemes that embrace microfinance support. Community mobilisation interventions can help to change behaviour associated with high risk of HIV infection. The many laws, policies, and practices that stigmatise and discriminate against people living with HIV and key populations must be challenged and removed. Civil society and activism, the anchor sheet for years of the HIV/AIDS response, is under threat through restrictive laws and funding cuts, so the global HIV community must show solidarity with civil society and reaffirm its place in the HIV/AIDS response. Young people are those most affected by the HIV epidemic, and countries and initiatives worldwide need to recruit and train the younger generation and use their language and their tools (social media and encounter apps) to leverage the fight against HIV/AIDS. Innovations in science and technology are more likely to be accepted and taken up by the younger generation who now need to take on a leadership role and carry the torch for ending the HIV epidemic by 2030.

Is there a cure or vaccine to end the AIDS epidemic?

The success of ART has led to the consideration of whether a cure for AIDS might be possible. Although ART causes complete or near-complete inhibition of HIV replication, the virus persists in long-lived infected resting T cells, which contain integrated, transcriptionally latent HIV DNA, and these serve as a reservoir for on-going infection³⁹. Cure in HIV/AIDS is usually defined as *sterilising* (all latent HIV-infected cells are eliminated) or *functional* (latent HIV persists but viraemia is very low or absent without the use of ART). The only reported case of a sterilising cure is the Berlin patient, an HIV-infected man given a bone marrow transplant from a naturally HIV-resistant donor for acute myeloid leukaemia³⁹. While an interesting observation, such an invasive intervention could never at present be widely implemented. The focus has therefore been on the possibility of a functional cure.

The first report of a functional cure was that of an infant born to an HIV-infected woman who received ART within 30 hours of birth (the Mississippi baby), with the child having an undetectable viral load after ART was discontinued at the age of 18 months⁴⁰. This was followed by speculation that very early treatment might prevent the formation of latent reservoirs for HIV, at least in infants with an immature immune system. Unfortunately, recent evidence of viral rebound in the Mississippi child has shattered hopes for this approach⁴¹. At present, no cure for HIV is in sight, although the research continues. Ultimately, getting rid of HIV from latent reservoirs will need a combination approach both for activation of the virus and for clearance, a biomedical strategy known as “shock and kill”⁴².

Some have argued that the only guarantee of a sustained end to the AIDS epidemic will be a combination of non-vaccine prevention

methods and the deployment of a safe and effective HIV vaccine⁴³. Ever since HIV was discovered as the cause of AIDS in 1983–1984, intensive work has been undertaken to develop a preventive vaccine. Yet, to date, only three vaccines have completed clinical efficacy trials. The first two candidate vaccines failed their efficacy trials⁴⁴, while the third vaccine (RV144) showed modest efficacy at 31% in preventing acquisition of HIV infection⁴⁵. Despite these setbacks and the inherent difficulties in developing an effective HIV vaccine, the science continues with optimism that theory and empiricism will ultimately coalesce for a good end result⁴⁶.

Conclusion

We believe that the goal of ending the HIV/AIDS epidemic by 2030 is achievable and should gather momentum. The WHO’s “3 by 5” strategy, aiming to provide ART for 3 million people by 2005, was thought to be wildly over-ambitious and unrealistic by some. However, in reality, it inspired concerted international action and huge progress, leading to momentum that ultimately resulted in 17 million people receiving ART by 2015². The current bold ambitious target for HIV/AIDS is similarly needed to inspire, energise, and mobilise communities.

Modelling studies suggest that meeting the 90-90-90 targets using current health technologies will enable the goal of ending HIV/AIDS by 2030 to be achieved, even without a therapeutic means of cure or a preventive vaccine¹³. We have come to this point because i) the diagnosis of HIV is based on rapid, easy-to-use diagnostic tests that are truly point of care, allowing decentralisation and task sharing and therefore wide coverage, ii) ART is now a single, once-a-day pill that is effective, safe, and relatively non-toxic and hence can be used in asymptomatic persons with or without HIV to both treat HIV and prevent the transmission of infection, and iii) there has been significant engagement by the community affected by HIV resulting in dramatically reduced drug pricing and increased access, significant international donor interest in the form of the GFATM (the Global Fund to Fight AIDS, Tuberculosis, and Malaria) and PEPFAR (the US President’s Emergency Plan for AIDS Relief), and successful programme delivery in many settings.

Diagnosing the millions of people who do not know that they have HIV and starting and retaining those people on ART are daunting prospects and will require increased focus and efficiency including strong political will, scale up of human resources, logistic capacity, better-functioning health systems, innovations in service delivery including community- and patient-driven initiatives, and additional financial resources. Importantly, finding practical ways of reaching those who lie outside the rims of the traditional health services, “the how to deliver”, will need focused attention. This includes populations affected by conflict and humanitarian crises.

Over the past 30 years, funding for the HIV/AIDS response in low- and middle-income countries has risen from almost nothing to \$19 billion per annum, although it is estimated that this needs to rise further to \$36 billion per annum to achieve the UN goal of ending the AIDS epidemic by 2030². In many settings, though, the

reality is that less than half of the resources are spent on ensuring access to early treatment and the price tag to optimise treatment coverage may well be within the current funding envelope. It is our opinion that a substantial part of HIV/AIDS funding, including that from the Global Fund and PEPFAR, is spent on non-evidence-based interventions, and this has to change with monitoring and evaluation ensuring that resources are well utilised. Efficient use of funds also means controlling corruption and preventing the deviation of resources to activities other than HIV and health system strengthening.

In summary, in the last decade, the HIV/AIDS community has shown itself capable of rising to a plethora of challenges; in the absence of complacency, we should be able to accelerate progress over the next two decades and end the AIDS epidemic.

Author contributions

ADH, ABS, and RZ wrote the first draft and all authors (ADH, ABS, KCT, HT, NTKK, KTS, and RZ) helped to write the subsequent and final drafts. All authors have read and approved the final paper for submission. All authors are responsible for the views expressed in this paper and they do not necessarily represent the decisions or policies of their institutions.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- United Nations: **Transforming our world: the 2030 agenda for sustainable development**. 2015.
[Reference Source](#)
- Plot P, Abdool Karim SS, Hecht R, *et al.*: **Defeating AIDS—advancing global health**. *Lancet*. 2015; **386**(9989): 171–218.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- UNAIDS: **Global AIDS Update. 2016**. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
[Reference Source](#)
- UNAIDS: **The Gap Report**. Geneva, Switzerland. Joint United Nations Programme on HIV/AIDS, 2014; 123.
[Reference Source](#)
- INSIGHT START Study Group; Lundgren JD, Babiker AG, *et al.*: **Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection**. *N Engl J Med*. 2015; **373**(9): 795–807.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, *et al.*: **A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa**. *N Engl J Med*. 2015; **373**(9): 808–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Cohen MS, Chen YQ, McCauley M, *et al.*: **Prevention of HIV-1 infection with early antiretroviral therapy**. *N Engl J Med*. 2011; **365**(6): 493–505.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Jia Z, Mao Y, Zhang F, *et al.*: **Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–11): a national observational cohort study**. *Lancet*. 2013; **382**(9899): 1195–203.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Celum C, Morrow RA, Donnell D, *et al.*: **Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial**. *Ann Intern Med*. 2014; **161**(1): 11–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Suthar AB, Lawn SD, del Amo J, *et al.*: **Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis**. *PLoS Med*. 2012; **9**(7): e1001270.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Abdool Karim SS: **Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy**. *N Engl J Med*. 2015; **373**(9): 875–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ahmed S, Kim MH, Abrams EJ: **Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach**. *Curr Opin HIV AIDS*. 2013; **8**(5): 474–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- UNAIDS: **90-90-90. An ambitious treatment target to help end the AIDS epidemic**. UNAIDS, Geneva, Switzerland. 2014.
[Reference Source](#)
- Suthar AB, Granich RM, Kato M, *et al.*: **Programmatic Implications of Acute and Early HIV Infection**. *J Infect Dis*. 2015; **212**(9): 1351–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Suthar AB, Ford N, Bachanas PJ, *et al.*: **Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches**. *PLoS Med*. 2013; **10**(8): e1001496.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- MacPherson P, Lalloo DG, Webb EL, *et al.*: **Effect of optional home initiation of HIV care following HIV self-testing on antiretroviral therapy initiation among adults in Malawi: a randomized clinical trial**. *JAMA*. 2014; **312**(4): 372–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Pascom AR, Dutra de Barros CH, Lobo TD, *et al.*: **Point-of-care HIV tests done by peers, Brazil**. *Bull World Health Organ*. 2016; **94**(8): 626–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Palella FJ Jr, Delaney KM, Moorman AC, *et al.*: **Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators**. *N Engl J Med*. 1998; **338**(13): 853–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Geneva: World Health Organization: **Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection**. Recommendations for a public health approach. WHO, Geneva, Switzerland, 2013.
[PubMed Abstract](#)
- ENCORE1 Study Group; Carey D, Puls R, *et al.*: **Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study**. *Lancet Infect Dis*. 2015; **15**(7): 793–802.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Sax PE, Wohl D, Yin MT, *et al.*: **Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials**. *Lancet*. 2015; **385**(9987): 2606–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Geneva: World Health Organization: **Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV**. WHO, Geneva, Switzerland, 2015.
[PubMed Abstract](#)
- Geneva: World Health Organization: **Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach**. Second Edition, WHO, Geneva, Switzerland, 2016.
[PubMed Abstract](#)
- Owen A, Rannard S: **Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy**. *Adv Drug Deliv Rev*. 2016; **103**: 144–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Harries AD, Makombe SD, Libamba E, *et al.*: **Why did the scale-up of HIV treatment work? A case example from Malawi**. *J Acquir Immune Defic Syndr*. 2011; **57**(Suppl 2): S64–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- World Health Organization: **Global health sector response to HIV, 2000 – 2015**.

Focus on innovations in Africa. WHO, Geneva Switzerland, 2015.

Reference Source

27. Beyrer C, Bekker LG, Pozniak A, *et al.*: **Pre-exposure prophylaxis works--it's time to deliver.** *Lancet.* 2015; **385**(9977): 1482–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. **F** Grant RM, Lama JR, Anderson PL, *et al.*: **Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.** *N Engl J Med.* 2010; **363**(27): 2587–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. **F** Molina JM, Capitant C, Spire B, *et al.*: **On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.** *N Engl J Med.* 2015; **373**(23): 2237–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. **F** Baeten JM, Donnell D, Ndase P, *et al.*: **Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.** *N Engl J Med.* 2012; **367**(5): 399–410.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
31. **F** Thigpen MC, Kebaabetswe PM, Paxton LA, *et al.*: **Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.** *N Engl J Med.* 2012; **367**(5): 423–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
32. **F** Choopanya K, Martin M, Suntharasamai P, *et al.*: **Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.** *Lancet.* 2013; **381**(9883): 2083–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. **F** Marrazzo JM, Ramjee G, Richardson BA, *et al.*: **Tenofovir-based preexposure prophylaxis for HIV infection among African women.** *N Engl J Med.* 2015; **372**(6): 509–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. **F** Auvert B, Taljaard D, Lagarde E, *et al.*: **Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.** *PLoS Med.* 2005; **2**(11): e298.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. **F** Bailey RC, Moses S, Parker CB, *et al.*: **Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.** *Lancet.* 2007; **369**(9562): 643–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. Gray RH, Kigozi G, Serwadda D, *et al.*: **Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.** *Lancet.* 2007; **369**(9562): 657–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. **F** Tobian AA, Serwadda D, Quinn TC, *et al.*: **Male circumcision for the prevention of HSV-2 and HPV infections and syphilis.** *N Engl J Med.* 2009; **360**(13): 1298–309.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. **F** Remme M, Siapka M, Vassall A, *et al.*: **The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review.** *J Int AIDS Soc.* 2014; **17**(1): 19228.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. Kent SJ, Reece JC, Petravic J, *et al.*: **The search for an HIV cure: tackling latent infection.** *Lancet Infect Dis.* 2013; **13**(7): 614–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. **F** Persaud D, Gay H, Ziemniak C, *et al.*: **Absence of detectable HIV-1 viremia after treatment cessation in an infant.** *N Engl J Med.* 2013; **369**(19): 1828–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. Giacomini V, Trabattoni D, Zanchetta N, *et al.*: **No cure of HIV infection in a child despite early treatment and apparent viral clearance.** *Lancet.* 2014; **384**(9950): 1320.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Lewin SR, Deeks SG, Barré-Sinoussi F: **Towards a cure for HIV--are we making progress?** *Lancet.* 2014; **384**(9939): 209–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Fauci AS, Marston HD: **Ending AIDS--is an HIV vaccine necessary?** *N Engl J Med.* 2014; **370**(6): 495–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Baden LR, Dolin R: **The road to an effective HIV vaccine.** *N Engl J Med.* 2012; **366**(14): 1343–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. **F** Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, *et al.*: **Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.** *N Engl J Med.* 2009; **361**(23): 2209–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. Fauci AS, Marston HD: **PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.** *Science.* 2015; **349**(6246): 386–7.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Fabio Mesquita**

School of Medicine, University of Sao Paulo, Sao Paulo, Brazil

Competing Interests: No competing interests were disclosed.

2. **Ali Zumla**

Division of Infection and Immunity, University College London, London, UK

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research